Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.77 USD | -2.08% | -1.31% | +23.66% |
May. 03 | Aileron Therapeutics Closes Direct Offering of Shares, Warrants | MT |
May. 01 | Transcript : Aileron Therapeutics, Inc. - Special Call |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 79.71M |
---|---|---|---|---|---|
Net income 2024 * | -23M | Net income 2025 * | -27M | EV / Sales 2024 * | - |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-1.04
x | P/E ratio 2025 * |
-2.08
x | Employees | 15 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 93.92% |
Latest transcript on Aileron Therapeutics, Inc.
1 day | -2.08% | ||
1 week | -1.31% | ||
Current month | -17.14% | ||
1 month | -11.29% | ||
3 months | -19.62% | ||
6 months | +96.35% | ||
Current year | +23.66% |
Managers | Title | Age | Since |
---|---|---|---|
Brian Windsor
CEO | Chief Executive Officer | 57 | 23-10-30 |
David Annis
CTO | Chief Tech/Sci/R&D Officer | 51 | 07-10-31 |
Director/Board Member | 53 | 14-08-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 68 | 19-06-18 | |
Alan Musso
BRD | Director/Board Member | 62 | 23-10-30 |
Brian Windsor
CEO | Chief Executive Officer | 57 | 23-10-30 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-17 | 3.77 | -2.08% | 19,489 |
24-05-16 | 3.85 | -1.28% | 57,080 |
24-05-15 | 3.9 | 0.00% | 20,862 |
24-05-14 | 3.9 | +0.52% | 48,242 |
24-05-13 | 3.88 | +1.57% | 17,117 |
Delayed Quote Nasdaq, May 17, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+23.66% | 80.1M | |
+9.42% | 115B | |
+11.84% | 106B | |
-1.05% | 21.96B | |
-14.15% | 21.84B | |
-5.29% | 19.21B | |
-4.16% | 18.08B | |
-38.29% | 17.71B | |
+7.99% | 14.32B | |
+36.24% | 12.42B |
- Stock Market
- Equities
- ALRN Stock